Cost-Effectiveness Analysis of Triple Therapy with Protease Inhibitors in Treatment-Naive Hepatitis C Patients

被引：0
|
作者：
Antonio Blázquez-Pérez
Ramón San Miguel
Javier Mar
机构：
[1] Agencia Española de Medicamentos y Productos Sanitarios,Departamento de Medicamentos de Uso Humano
[2] Complejo Hospitalario de Navarra,Department of Pharmacy
[3] Hospital Alto Deba,Clinical Management Service
来源：
PharmacoEconomics | 2013年 / 31卷
关键词：
Triple Therapy; Probabilistic Sensitivity Analysis; Dual Therapy; Telaprevir; Boceprevir;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：919 / 931
页数：12
相关论文
共 50 条
  • [1] Cost-Effectiveness Analysis of Triple Therapy with Protease Inhibitors in Treatment-Naive Hepatitis C Patients
    Blazquez-Perez, Antonio
    San Miguel, Ramon
    Mar, Javier
    [J]. PHARMACOECONOMICS, 2013, 31 (10) : 919 - 931
  • [2] COST-EFFECTIVENESS OF TRIPLE THERAPY WITH TELAPREVIR FOR THE TREATMENT OF TREATMENT-NAIVE GENOTYPE 1 CHRONIC HEPATITIS C PATIENTS IN GERMANY
    Stahmeyer, J. T.
    Schauer, S.
    Wirth, D.
    Fleischmann, J.
    Lee, S.
    Gavart, S.
    Bianic, F.
    Cure, S.
    Krauth, C.
    [J]. VALUE IN HEALTH, 2012, 15 (07) : A396 - A396
  • [3] THE COST-EFFECTIVENESS OF TELAPREVIR TRIPLE THERAPY IN TREATMENT OF NAIVE CHRONIC HEPATITIS C PATIENTS IN TURKEY
    Ozdemir, O.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A670 - A670
  • [4] Cost-effectiveness analysis of telaprevir triple therapy for treatment-naive patients with chronic hepatitis C based on the combined efficacy data of the ADVANCE and OPTIMIZE studies
    Buti, Maria
    Gros, Blanca
    Oyagueez, Itziar
    Andrade, Raul J.
    Angel Serra, Miguel
    Turnes, Juan
    Casado, Miguel A.
    [J]. HEPATOLOGY, 2013, 58 : 1133A - 1133A
  • [5] Management of treatment-naive chronic hepatitis C genotype 1 patients: a cost-effectiveness analysis of treatment options
    Cortesi, P. A.
    Ciaccio, A.
    Rota, M.
    Lim, J. K.
    De Salvia, S.
    Okolicsanyi, S.
    Vinci, M.
    Belli, L. S.
    Mantovani, L. G.
    Strazzabosco, M.
    [J]. JOURNAL OF VIRAL HEPATITIS, 2015, 22 (02) : 175 - 183
  • [6] New Protease Inhibitors for the Treatment of Chronic Hepatitis C A Cost-Effectiveness Analysis
    Liu, Shan
    Cipriano, Lauren E.
    Holodniy, Mark
    Owens, Douglas K.
    Goldhaber-Fiebert, Jeremy D.
    [J]. ANNALS OF INTERNAL MEDICINE, 2012, 156 (04) : 279 - U68
  • [7] Cost-Effectiveness of New Antiviral Regimens for Treatment-Naive US Veterans with Hepatitis C
    Chidi, Alexis P.
    Rogal, Shari
    Bryce, Cindy L.
    Fine, Michael J.
    Good, Chester B.
    Myaskovsky, Larissa
    Rustgi, Vinod K.
    Tsung, Allan
    Smith, Kenneth J.
    [J]. HEPATOLOGY, 2016, 63 (02) : 428 - 436
  • [8] COST-EFFECTIVENESS OF DIRECT-ACTING ANTIVIRALS FOR CHRONIC HEPATITIS C TREATMENT-NAIVE PATIENTS IN CHINA
    Wei, X.
    Feng, Y.
    Yang, L.
    [J]. VALUE IN HEALTH, 2019, 22 : S197 - S198
  • [9] Cost-effectiveness of combination therapy for naive patients with chronic hepatitis C
    Buti, M
    Casado, MA
    Fosbrook, L
    Wong, JB
    Esteban, R
    [J]. JOURNAL OF HEPATOLOGY, 2000, 33 (04) : 651 - 658
  • [10] Cost-effectiveness analysis of simeprevir in combination with peginterferon and ribavirin for treatment-naive chronic hepatitis C genotype 1 patients in Japan
    Kuwabara, Hiroyo
    Westerhout, Kirsten
    Treur, Maarten
    Cerri, Karin
    Mahlich, Joerg
    Yatsuhashi, Hiroshi
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2015, 18 (07) : 502 - 511
12345